---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-25-000062"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:24:09.673875+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q3 net income drops 57% YoY to $17.4M; adjusted EPS $0.93 vs $0.96

## Summary
- Net revenues of $191.8M, flat YoY vs $191.2M.
- GAAP net income of $17.4M ($0.37 diluted EPS) vs $40.4M ($0.78) in Q3 2024.
- Adjusted non-GAAP net income $44.7M ($0.93 diluted EPS) vs $49.6M ($0.96).
- BAQSIMI revenue grew 14% YoY; FDA approval and launch of iron sucrose injection noted.
- Nine-month 2025 GAAP net income $73.7M ($1.52 EPS) vs $121.6M ($2.32) prior year.

## SEC filing metadata
- accession: 0001297184-25-000062
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000062/0001297184-25-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000062/amph-20251106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-25-000062
- JSON: https://secwatch.observer/filing/0001297184-25-000062.json
- Plain text: https://secwatch.observer/filing/0001297184-25-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.